The peritoneal dialysis equipment market is estimated to be valued at USD 4.62 Bn in 2024 and is expected to reach USD 6.93 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6% from 2024 to 2031. The aging population suffering from renal disorders and the rising prevalence of end-stage renal disease (ESRD), particularly in developing nations, are key factors driving the growth of peritoneal dialysis equipment market.

Market Driver - Rising Prevalence of Kidney Disorders like ESRD and Acute Kidney Injury (AKI)

Increasing prevalence of chronic kidney diseases especially ESRD and AKI has emerged as one of the key drivers of the peritoneal dialysis equipment market.

According to latest estimates, over 2 million people suffer from ESRD globally with growing numbers in developing nations due to lack of preventive healthcare and risk factors like diabetes and hypertension going uncontrolled. Peritoneal dialysis has established itself as an effective treatment modality for ESRD patients especially in home settings and as a permanent or temporary solution before kidney transplantation.

As per WHO, over 13 million cases of AKI are reported annually across the world. Even though majority of AKI cases improve with conservative treatment, the rising burden on healthcare systems due to longer hospital stays is undisputed.

Peritoneal dialysis provides a superior alternative for AKI treatment compared to hemodialysis by enabling continuous blood purification without the need for vascular access.

With growing prevalence of risk factors globally, the incidence of both chronic and acute kidney diseases is expected to rise significantly creating sustained demand in the peritoneal dialysis equipment market in coming years.

Market Driver - Growing Elderly Population and Prevalence of Diabetes and Hypertension

Rapid aging population coupled with rising trends of lifestyle diseases another key macro-driver influencing the peritoneal dialysis market size. According to latest UN population data, the share of world's population aged over 60 years will double from 12% to 22% between 2015 and 2050.

Notably, over 80% of kidney failures occur in people aged over 60 as elderly people have higher kidney dysfunction risks. Global prevalence of diabetes and pre-diabetes has risen dramatically over the past few decades and now affecting over half billion people. Hypertension is even more widespread with an estimated 1.13 billion hypertensive population globally as per WHO estimates.

As these non-communicable diseases take a toll on kidney health in aging populace, both incidence and prevalence of CKD and ESRD has multiplied considerably. This has driven the need for simple dialysis modalities like peritoneal dialysis which allow self-care at home with ease and mobility.

Overall, confluence of demographic and disease trends has not only expanded the pool of dialysis patients but also the pool suitable for automated peritoneal dialysis to self-manage their healthcare requirements.

Market Challenge - Risk of Complications like Peritonitis with Peritoneal Dialysis

One of the key challenges faced by the peritoneal dialysis equipment market is the risk of various complications that can arise from using peritoneal dialysis as a treatment method. Peritonitis, which refers to the infection or inflammation of the peritoneum, is a severe complication that can occur in up to 30% of peritoneal dialysis patients over time.

When peritonitis sets in, patients often have to be hospitalized for IV antibiotic treatment. This disruption to treatment can significantly impact the patient's quality of life. The catheter used for continuous ambulatory peritoneal dialysis also poses risks such as exit site or tunnel infection. If severe enough, such infections may require the catheter to be removed.

The risk of peritonitis and other infections means patients have to be very careful about aseptic techniques during dialysis exchanges. Minor contamination can potentially lead to inflammation. This risk factor and the treatment challenges associated with peritonitis cases can negatively impact the demand for peritoneal dialysis systems and affect growth for the peritoneal dialysis equipment market.

Market Opportunity - Technological Advancements in Dialysis Equipment for Market Opportunities

The peritoneal dialysis equipment market has strong opportunities arising from ongoing technological advancements in this field. One prominent area is the development of new peritoneal dialysis solutions that are more biocompatible and cause minimal inflammation or damage to the peritoneal membrane. This can help reduce the risk of peritonitis and other complications.

Another focus area is the integration of advanced connectivity features in dialysis cyclers and systems. The addition of wireless data transfer capabilities and remote monitoring functions allow patients to receive treatment while staying at home. This shift to ‘home hemodialysis’ is more convenient and improves patient comfort.

We are also seeing infusion sets and catheters equipped with anti-microbial properties to inhibit bacterial attachment and exit-site infection. With continued innovations, the dialysis treatment process will become safer and more effective over time. This provides ample opportunities for all stakeholders in the peritoneal dialysis equipment market to introduce novel products and clinical solutions.

One of the most successful strategies adopted was focus on innovation and new product launches. For instance, Baxter launched newer versions of its cycler machines and peritoneal dialysis solutions in 2015 and 2017 that were smaller, more portable and integrated touchscreen controls. This made home therapy more convenient for patients. These launches helped Baxter strengthen its leadership position in the market.

Another major player Fresenius Medical Care adopted an acquisition strategy to rapidly expand its product portfolio and geographic reach. In 2014, it acquired Liberty Dialysis to enhance its presence in the US home market. Then in 2017, it acquired NxStage Medical, which added innovative acute and home therapies to its offerings. This strengthened Fresenius' complete renal care portfolio across settings.

Players also focused intensively on partnerships and collaborations. For example, in 2010 DaVita partnered with Novartis to private label its diabetes drug and bundle it with PD treatments. This made therapy more accessible and affordable for patients. More recently in 2019, Baxter partnered with Resmed to integrate personalized respiratory therapies into home systems. This helped address comorbid conditions and improve patient outcomes.

Insights, By Product Type: Convenience and Cost-Effectiveness Drive Consumables Demand

In terms of product type, consumables segment contributes 67.6% share of the market in 2024, owning to their convenience and cost-effectiveness compared to systems. Consumables such as peritoneal dialysis solution, transfer sets, and catheters are single-use disposable items that are replaced regularly during peritoneal dialysis treatment. This makes them more practical and suitable for home care settings compared to expensive capital equipment like cyclers.

It also eliminates costs associated with equipment sterilization, maintenance, and repairs. As a result, consumables see high recurring demand from patients performing peritoneal dialysis at home or in centers.

With growing preference for home-based therapies due to the flexibility and independence they provide, consumable sales are expected to rise, cementing their leadership over more complex product segments.

Insights, By Treatment Type: Flexibility Drives CAPD Equipment Popularity

In terms of treatment type, continuous ambulatory peritoneal dialysis (CAPD) equipment segment is estimated to hold 53.9% share of the market in 2024, owing to the flexibility it provides patients. CAPD is a simple, manual process that does not require specialized equipment or training to operate.

Patients can conduct multiple 2-liter bag exchanges per day independently, allowing them to integrate treatment into their regular daily activities and routines. This makes CAPD very accommodating of active lifestyles and travel. With equipment only including simple supplies like dialysate bags, tubing, and a catheter, CAPD proves a cost-effective solution as well.

Its convenience has resulted in strong adoption rates, particularly among elderly patients living independently or in assisted living facilities. As such, CAPD equipment maintains a clear lead over automated modalities that present constraints on mobility and freedom.

Insights, By End User: Independence Drives Home Care Demand

In terms of end user, home care settings contribute the highest share of the market owing to the independence it provides to patients. Conducting dialysis at home rather than visiting centers on a fixed schedule allows patients complete control over their daily routines. They have flexibility to receive treatment as per individual schedules without disrupting work or socializing.

This independence helps maintain a sense of normalcy and improved quality of life compared to being restricted by center timing. With majority of peritoneal dialysis now shifting to simpler, user-friendly modalities like CAPD, most patients can independently manage therapy at home with basic training. This has made home-based care the compelling mode of treatment. Support from reimbursement programs and home health agencies further aid its accessibility.

 As independence remains a critical priority for patients with chronic conditions, home settings will continue dominating end user demand.

• The rising cases of ESRD and hypertension in the U.S. are boosting the demand for dialysis products. According to the CDC (2019), 47% of the U.S. population (116 million) suffer from hypertension, leading to kidney complications.
• Regional Insights: North America held the largest market share due to advanced healthcare infrastructure and high ESRD prevalence.
• The shift towards telemedicine has allowed for remote monitoring of peritoneal dialysis patients, enhancing patient care and adherence.
• Increased investments in R&D by key players are leading to more efficient and safer dialysis equipment.

The major players operating in the peritoneal dialysis equipment market include Baxter International Inc., Fresenius Medical Care AG & Co. KGaA, Terumo Corporation, Medtronic plc, Utah Medical Products, Inc., Polymedicure, Cook, Cardiomed, Angiplast, Merit Medical Systems, Amecath, Newsol Technologies Inc., Renax Biomedical Tech. Co., Ltd., Jilin Province Maida Medical Equipment Co., Ltd., Kelun Group, Huaren Pharmaceutical Co., Ltd., Mitra Industries Pvt. Ltd., EQUIPOS DE BIOMEDICINA DE MÉXICO S.A DE C.V, Advin Health Care, and AWAK Technologies.

• In September 2021, Fresenius Medical Care entered into a strategic distribution partnership with JMS Co. Ltd. in Japan. This agreement focuses on distributing Fresenius Medical Care's innovative home dialysis therapies, including automatic peritoneal dialysis systems, which have already received approvals from the U.S. FDA and European CE Mark. The partnership aims to address the growing demand for home dialysis in Japan, particularly driven by the country's aging population. This collaboration provides patients with a wider range of dialysis options that are more suited to their lifestyle and healthcare needs.
• In March 2021, Baxter International launched a new generation of peritoneal dialysis solutions aimed at improving patient outcomes. Baxter introduced systems like the HomeChoice Claria with the Sharesource remote patient management platform. This system enhances patient care by allowing clinicians to monitor PD treatments remotely and make adjustments without requiring patients to visit the clinic. This innovation is designed to improve patient outcomes, particularly in home-based dialysis settings, by offering real-time monitoring and data analysis.
• In October 2020, Fresenius Medical Care North America received FDA approval for their DELFLEX® peritoneal dialysis solutions, which use Biofine®, an innovative and more environmentally friendly bag material. This approval marked an important milestone in the company's efforts to enhance home dialysis products.
• In July 2020, Fresenius Medical Care announced the expansion of its home dialysis portfolio, particularly emphasizing the growth of peritoneal dialysis (PD) treatments. This expansion included increasing the availability of peritoneal dialysis solutions, highlighting their commitment to advancing home therapy options for patients with end-stage renal disease (ESRD). This was part of their broader strategy to enhance home-based care, which became even more significant during the COVID-19 pandemic as more patients opted for home dialysis to reduce clinic visits.

• By Product Type
  • Consumables
    • Peritoneal Dialysis Solution
    • Peritoneal Dialysis Transfer Sets
    • Peritoneal Dialysis Catheters
    • Others
  • Systems
• By Treatment Type
  • Continuous Ambulatory Peritoneal Dialysis (CAPD) Equipment
    • Dialysis Solution
    • Administration Sets
    • Catheters
  • Automated Peritoneal Dialysis (APD) Equipment
    • Cyclers
    • Tubing Sets
    • Drainage Bags
• By End User
  • Home Care Settings
  • Hospitals
  • Dialysis Centers